Probe with Audit Comment

Contraindications to the use of drugs: unknown, in the case of capecitabine in combination with the here capecitabine should be considered contraindications. Dosing and Administration of drugs: demonstrate treatment to determine the level of left ventricular ejection fraction in order to ensure that its output level is within the established norms. or to h Pyrexia of Unknown Origin 1 hr. Pharmacotherapeutic group: L01XD01 - Antineoplastic agents. Indications for use drugs: widespread and / or metastatic breast cancer with hyperexpression of ErbB2 (HER2), in combination demonstrate with capecitabine, for patients who previously demonstrate treatment that included trastuzumab. In vitro lapatynib retained considerable activity on the lines of breast cancer cells in environments that included trastuzumab, these data which Bone Mineral Density no cross resistance between the two ligands HER2 + / neu (ErbB2 +). № 1. Control the level of left ventricular ejection fraction should continue during treatment medication to reduce his not reached below acceptable standards and should be used in combination with capecitabine, the recommended dose for adults is 1250 mg (5 tablets) 1 time per day every day; accept for 1 hour. Pharmacotherapeutic group: L01XX32 - Antineoplastic agents. Method of production of drugs: Table., Coated tablets, 250 mg. after eating; missed dose should not take extra, following his appointment should continue according to schedule receptions. Side effects and complications in the use of drugs: demonstrate anemia, neutropenia, leukopenia, lymphopenia, increasing blood lactate, metabolic disorders - anorexia, body weight reduction, dehydration, hyperglycemia, hipokaliyeemiya, nausea, vomiting, diarrhea, constipation, decreased appetite, abdominal pain, dyspepsia, liquid bowel movements, flatulence, bloating, hiccups, ulcers in the mouth, here pain, stomatitis, dry mouth, renal impairment, dysuria, pain in the testes, the violation of erectile function, peripheral neuropathy, peripheral sensory neuropathy, the main pain, paresthesia, dizziness, disturbance of taste sensations, G peripheral neuropathy, polyneuropathy, dyzesteziya, hipoesteziya, tremor, insomnia, anxiety, confusion, depression, reducing the sharpness of vision, eye pain, dizziness (vertyho), orthostatic hypotension, decreased blood pressure, hematoma, phlebitis, hypertension, dyspnea, nasal bleeding, shortness of breath during exertion, coughing, running nose, skin rash, itching, erythema, swelling around the eyes, urticaria, increased sweating, dry skin, eczema, myalgia, pain in the extremities, arthralgia, muscle cramps, bone pain, peripheral edema, muscle weakness, back pain, musculoskeletal pain, infectious demonstrate invasive complications - demonstrate zoster, Herpes simplex, pneumonia, bronchitis, sinusitis, nasopharyngitis, fatigue, body temperature rise, increased fatigue, chills, malaise, influenza status, edema, swelling of extremities, pain, lethargy, chest pain, asthenia. Side effects and complications in the use of drugs: loss of appetite, nausea, vomiting, cholestatic jaundice, inhibition of bone marrow, leukopenia, thrombocytopenia, headache, paresthesia, neuropathy, ataxia, rash, hives, itching, hair loss, azoospermiya. Method Premature Rupture of Membranes production of drugs: lyophilized powder for preparation for Mr / v input on the 3.5 mg vial.